ICER update on Duchenne drugs pushes up price estimates for Exondys 51, Emflaza ahead of July panel review
Increasingly influential drug cost-effectiveness watchdog ICER still doesn’t think that the drugs approved to treat Duchenne muscular dystrophy have so far proved their value to patients. On Thursday, they used significantly higher price estimates for two therapies in their models, making them look even less attractive — and acknowledged that the estimates used in their draft report in May were incorrect.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.